The global diabetic retinopathy market is estimated to grow at a CAGR of over 6% during the forecast period. The eye disease associated with diabetic patients is diabetic retinopathy. It occurs when there is long term diabetes and which damages the retina. Without timely treatment, the disease may lead to various impairments in eyes such as cloudy vision, bleeding in the eyes, and can even permanently damage the retina and can eventually lead to blindness.
The factors that primarily drive the growth of the global diabetic retinopathy industry include, rising prevalence of diabetes, rise in geriatric population, growth in incidence of blindness due to diabetes, and focus on increasing awareness that facilitates early diagnosis to control the diseases. However, some of the factors such as extended approval time for drugs and high costs of treatment that challenge the growth of the global diabetic retinopathy market.
Browse the full report description of "Global Diabetic Retinopathy Market Size, Share & Trends Analysis Report by Type (Proliferative Diabetic Retinopathy and Non-Proliferative Diabetic Retinopathy), By Management (Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, and Vitrectomy), Forecast 2019-2025" at https://www.omrglobal.com/industry-reports/diabetic-retinopathy-market
Further, based on the management segment of the global diabetic retinopathy market, the Anti-VEGF holds the most considerable share in the market. This is attributed to the high applicability of the drug in the treatment of diseases for early diagnosis and faster recovery. Lucentis is among one of the most commonly used anti-VEGF as its favorable outcomes. Thus, anti-VEGF is likely to register growth in the market.
Moreover, the laser is also a highly effective treatment method, due to which it is also preferred amongst patients. Thus, the technological advancement and availability of advanced and improved drugs and equipment are further projected to foster segmental growth global diabetic retinopathy market during the forecast period. Based on geography, North America is estimated to hold considerable share followed by Europe, attributing to the expanding healthcare infrastructure along with favorable reimbursement framework in the region.
Besides, F. Hoffmann-La Roche AG, Boehringer Ingelheim International GmbH, Bayer AG, Novartis International AG, Regeneron Pharmaceuticals Inc., Oxurion N.V.,and Pfizer Inc.are among the key companies of the market, that are adopting several organic and inorganic growth strategies such as product launches & developments, partnerships, agreements, and acquisitions to strengthen their existing product line and maintain a competitive position in the global diabetic retinopathy market. Also, the companies are adopting novel AI-based methods for the diagnosis and treatment of the eye of patients suffering from long term diabetic retinopathy.
Current Market Trends Covered in the Market Report:
Global Diabetic Retinopathy Market – Segmentation
By Type
By Management
Global Diabetic Retinopathy Market – Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy at https://www.omrglobal.com/request-sample/diabetic-retinopathy-market